Differential recruitment of the coactivator proteins CREB-binding protein and steroid receptor coactivator-1 to peroxisome proliferator-activated receptor gamma/9-cis-retinoic acid receptor heterodimers by ligands present in oxidized low-density lipoprotein

J Wigren, S Surapureddi, A G Olsson¹, C K Glass², S Hammarström and M Söderström

Division of Cell Biology, Department of Biomedicine and Surgery and ¹Division of Internal Medicine, Department of Internal Medicine and Care, Linköping University, S-581 85 Linköping, Sweden
²Department of Cellular and Molecular Medicine and Endocrinology and Division of Metabolism, Department of Medicine, University of California San Diego, 9500 Gilman Drive, La Jolla, California 92039-0651, USA

(Requests for offprints should be addressed to M Söderström, Cell Biology, IBK, Linköping University, S-58185 Linköping, Sweden; Email: mats@ibk.liu.se)

Abstract

Peroxisome proliferator-activated receptor gamma (PPARγ) colocalizes with oxidized low-density lipoprotein (LDL) in foam cells in atherosclerotic lesions. We have explored a potential role of oxidized fatty acids in LDL as PPARγ activators. LDL from patients suffering from intermittent claudication due to atherosclerosis was analyzed using HPLC and gas chromatography/mass spectrophotometry and found to contain 9-hydroxy- and 13-hydroxyoctadecadienoic acid (9- and 13-HODE), as well as 5-hydroxy-, 12-hydroxy- and 15-hydroxyeicosatetraenoic acid (5-, 12- and 15-HETE respectively). PPARγ was potently activated by 13(S)-HODE and 15(S)-HETE, as judged by transient transfection assays in macrophages or CV-1 cells. 5(S)– and 12(S)-HETE as well as 15-deoxy-Δ^{12,14}-prostaglandin J₂ also activated PPARγ but were less potent. Interestingly, the effect of the lipoxygenase products 13(S)-HODE and 15(S)-HETE as well as of the drug rosiglitazone were preferentially enhanced by the coactivator CREB-binding protein, whereas the effect of the cyclooxygenase product 15-deoxy-Δ^{12,14}-prostaglandin J₂ was preferentially enhanced by steroid receptor coactivator-1. We interpret these results, which may have relevance to the pathogenesis of atherosclerosis, to indicate that the lipoxygenase products on the one hand and the cyclooxygenase product on the other exert specific effects on the transcription of target genes through differential coactivator recruitment by PPARγ/9-cis retinoic acid receptor heterodimer complexes.

Journal of Endocrinology (2003) 177, 207–214

Introduction

Peroxisome proliferator-activated receptors (PPARs) are members of the steroid hormone receptor superfamily, and belong to a subgroup that comprises the thyroid hormone receptor, all-\textit{trans} retinoic acid receptor, 9-cis retinoic acid receptor (RXR), vitamin D₃ receptor and several orphan receptors (Glass 1994). Three mammalian PPAR isotypes (PPARα, PPARδ (NUC-1) and PPARγ) have been cloned (Green 1995). PPARs regulate genes encoding enzymes involved in lipid metabolism and probably play an important role in lipid homeostasis. They are activated by long-chain fatty acids and a group of structurally diverse substances termed peroxisome proliferators. Antidiabetic thiazolidinediones and 15-deoxy-Δ^{12,14}-prostaglandin J₂ (15-deoxy-Δ^{12,14}-PGJ₂) bind specifically to PPARγ and promote terminal differentiation of preadipocytes (Forman et al. 1995, Klierwer et al. 1995). The latter compound is a metabolite of prostaglandin D₂ (PGD₂) (Fitzpatrick & Wynalda 1983, Kikawa et al. 1984) and it has been suggested to be a natural PPARγ ligand (Forman et al. 1995, Klierwer et al. 1995). It has not yet been demonstrated, however, that adipocytes produce PGD₂, a precursor of 15-deoxy-Δ^{12,14}-PGJ₂. PGD₂ is, on the other hand, a major arachidonic acid metabolite in macrophages (McGuire et al. 1985). Earlier investigations (Ricote et al. 1998b) have shown that expression of PPARγ is increased in activated macrophages and that this receptor attenuates certain macrophage functions (Jiang et al. 1998). Moreover, it was found (Nagy et al. 1998) that PPARγ is activated by oxidized low-density lipoprotein (LDL) and two hydroxy acids, 9- and 13-hydroxyoctadecadienoic acid (HODE), and recent work has demonstrated that lysophosphatidic acid binds to and activates PPARγ...
PGJ2 apparently induced interaction of PPAR(1) element that is recognized by the PPARγ/RXRα heterodimer (Tontonoz et al. 1998). It has been noted that 15-deoxy-Δ12,14-PGJ2 in combination with the RXRα-specific ligand LG268 (Boehm et al. 1995) acts through the CD36 promoter DR-1 element to stimulate CD36 expression (Nagy et al. 1998). In addition, it was observed (Ricote et al. 1998a) that PPARγ is expressed in foam cells from human atherosclerotic lesions. Thus PPARγ ligands may play a role in the pathogenesis of atherosclerosis. We performed experiments to determine the endogenous content of selected monohydroxy acids in LDL isolated from a group of patients diagnosed with intermittent claudication and noted the presence of 9- and 13-HODE as well as of 5-hydroxy-, 12-hydroxy- and 15-hydroxyeicosatetraenoic acid (5-, 12- and 15-HETE respectively). Transient transfection assays, demonstrated that 13(S)-HODE and 15(S)-HETE, in particular, are potent PPARγ activators in macrophages. Interestingly, the lipoxygenase products 13(S)-HODE and 15(S)-HETE appeared to induce preferential interaction of PPARγ/RXRα heterodimers with CREB-binding protein (CBP), whereas the cyclooxygenase product 15-deoxy-Δ12,14-PGJ2 apparently induced interaction of PPARγ/RXRα with steroid receptor coactivator (SRC)-1.

Materials and Methods

Chemicals

The following commercial sources were used: eicosanoids and HODEs, Cayman, Ann Arbor, MI, USA; silicic acid (Biosil HA); BioRad, Richmond, CA, USA; platinum dioxide, Aldrich Chemical Co., Milwaukee, WI, USA; N-bis-trimethylsilyltrifluoroacetamide, Supelco, Bellefonte, PA, USA; restriction enzymes, Life Technologies; [35S]methionine, Amersham; reduced glutathione (GSH)-Sepharose, Pharmacia Biotech; luciferin, BioOrbit, Turku, Finland; and LG69, Ligand Pharmaceuticals, San Diego, CA, USA. All other chemicals were purchased from Sigma. Rosiglitazone was a gift from GlaxoSmithKline.

Cell culture

RAW 264·7 murine macrophages obtained from the American Type Culture Collection (Rockville, MD, USA) were cultured in high-glucose Dulbecco’s modified Eagle’s medium (DMEM; Gibco, New York, NY, USA) supplemented with 10% fetal calf serum (Gibco), 50 U/ml penicillin and 50 µg/ml streptomycin in an atmosphere containing 8% CO2. CV-1 cells were cultured in low-glucose DMEM in an atmosphere containing 5% CO2.

Analysis of LDL monohydroxy acids

LDL was prepared from venous blood (Havel et al. 1955) drawn from eight males, aged 45–65 years, with intermittent claudication, a condition characterized by atherosclerotic lesions of iliac and femoral arteries. The patients were recruited from a health-screening activity involving more than 20,000 participants in the city of Linköping, Sweden. Specific questions were asked regarding symptoms of intermittent claudication. The diagnosis was confirmed by physiological tests (e.g. ankle–brachial blood pressure and treadmill tests). The patients had given informed consent and the study was approved by a local ethics committee (approval no. 88–210). The LDL (4.5–7.5 mg protein) from three patients was pooled and analyzed by procedures described elsewhere (Wang & Powell 1991, Wang et al. 1992). The antioxidant propyl gallate (50 µM) was present during preparation and extraction of LDL (Folch et al. 1957). After extraction solvents were evaporated under argon, samples were redissolved in 0.2 mol/l sodium methoxide in methanol, and 200 ng methyl 14-hydroxy-10,13-nonadecadienoate (14h-19:2 Me) (prepared from nonadecadienoic acid (Funk & Powell 1985)) were added as internal standard. In one experiment, classes of lipids from the pooled LDL of two patients (3–5 mg protein) were separated on amino-propyl cartridges (Kaluzny et al. 1985) before sodium methoxide treatment. After 1 h at room temperature, the solution was neutralized with acetic acid, evaporated to 0.3 ml, and diluted with 1.7 ml 50 mmol/l Tris–buffer (pH 7.0). Transesterified acids were extracted three times with dichloromethane, solvents were evaporated under argon, and residues were redissolved in ethyl acetate: hexane (3:47 v/v) and applied to silicic acid (Biosil HA) columns. Fatty acid and hydroxy acid methyl esters, eluted with ethyl acetate:hexane (3:47 v/v), were analyzed by reverse-phase HPLC (RP–HPLC) on a C18 Nucleosil column (2·1 × 100 mm, 5 µm particles) (Macherey-Nagel Co, Düren, Germany) using a gradient of 30–85% acetonitrile in water (v/v) supplemented with 0.01% acetic acid. A Hewlett Packard model 1090 liquid chromatograph with a built-in model 1040 diode array detector was used for these analyses and light absorbance of the column effluent was monitored between 200 and 600 nm. Hydroxy acid methyl esters eluted between 17 and 21 min were collected, dried under argon, redissolved in methanol and hydrogenated over platinum dioxide for 90 s. The catalyst was removed by centrifugation and samples were dried under argon and treated with 10 µl N-bis-trimethylsilyltrifluoroacetamide mixed with 10 µl pyridine at 50 °C for 60 min. They were then subjected to selected
ion monitoring (SIM) analysis on a Hewlett Packard 5890A gas chromatograph, connected to a Hewlett Packard 5790B quadrupole mass spectrometer with 70 eV electron impact ionization. An Ultra-2 capillary column (25 m × 0.2 mm) was used at 235 °C.

**Semiquantitative analyses of hydroxy acids**

The concentrations of hydroxy acids in LDL were calculated from the ratio of the ion labeled with an asterisk in Table 1 to the ion at m/z 329 in 14h-19:0 Me. In order to compensate for differences in relative abundance of the ions labeled with an asterisk and that of m/z 329 a correction ratio (Table 1) was determined by analyzing equal amounts of the authentic reference compound and 14h-19:0 Me.

**Preparation of [35S]methionine-labeled CBP(1–450) and SRC-1**

pcDNA3-CBP(1–450), encoding amino acids 1–450 of CBP, was prepared from pcDNA3-CBP by restriction cutting with EcoRI. The resulting CBP fragment was ligated to pcDNA3 (Invitrogen) previously cut with EcoRI. The construct was checked for orientation of the insert and used as template to prepare [35S]methionine-labeled CBP(1–450) by in vitro transcription and translation, using the TntS Coupled Reticulocyte Lysate System (Promega). pcDNA3-SRC-1 was similarly used to prepare [35S]methionine-labeled SRC-1.

**Glutathione S-transferase (GST)-pulldown assay**

We used the GST-pulldown assay (DiRenzo et al. 1997, Krey et al. 1997) to identify ligands of PPARγ. To generate GST-PPARγ fusion protein, mouse PPARγ cDNA was inserted into the Nol–HindIII sites of pGEX-KG, and PPARγ was then expressed in E. coli, strain Y1090. The bacteria were lysed by sonication in buffer (50 mmol/l Tris–HCl pH 7.4, 1.5 mmol/l EDTA, 10% glycerol, 0.4 mol/l NaCl, 0.1 mmol/l dithiothreitol (DTT)) containing the following protease inhibitors: 0.5 mmol/l polymethylsulfonyl fluoride, 1 mmol/l benzamidine, 10 µg/ml leupeptin, 10 µg/ml antipain and 10 µg/ml aprotinin. The lysates were centrifuged at 100 000 g for 60 min in a SW 41 rotor in a Beckman L8–70 M ultracentrifuge (Fullerton, CA, USA), and the recombinant fusion protein was immobilized on GSH-Sepharose beads. These beads were then incubated with ligands in 100 µl CHAPS buffer (8 mmol/l Tris–HCl pH 7.4, 0.12 mol/l KCl, 8% glycerol, 4 mmol/l DTT, and 0.5% CHAPS) for 30 min at room temperature. Approximately 0.1 µCi [35S]methionine-labeled SRC-1 or [35S]methionine-labeled CBP(1–450) was then added and the incubation was continued for another hour at 4 °C. Excess labeled coactivator protein was washed away with CHAPS buffer after the incubation. After addition of SDS sample buffer, the samples were boiled for 2 min, and proteins were separated on 7.5% SDS-PAGE gels. Radioactivity was detected by autoradiography.

**Transfection experiments**

Expression plasmids encoding GAL4-DBD (amino acids 1–147)/mPPARγ-LBD (amino acids 174–475) (m indicates mouse) or GAL4-DBD (amino acids 1–147) as well as the reporter plasmid containing four GAL4 binding sites (17-mer) linked to the adenovirus E1b minimal promoter and a luciferase reporter gene are described in Forman et al. (1995) and DiRenzo et al. (1997). Another reporter

---

### Table 1 SIM of LDL hydroxy acids

<table>
<thead>
<tr>
<th>Hydroxy acids</th>
<th>9h–18:0</th>
<th>13h–18:0</th>
<th>5h–20:0</th>
<th>12h–20:0</th>
<th>15h–20:0</th>
<th>14h–19:0</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ion (m/z)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>173</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>203</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>215</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>229</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>259</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>301</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>313</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>315</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>329</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>343</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*SIM trace is shown in Fig. 2.*

9h-18:0, 9-hydroxyoctadecanoic acid; 13h-18:0, 13-hydroxyoctadecanoic acid; 5h-20:0, 5-hydroxyeicosanoic acid; 12h-20:0, 12-hydroxyeicosanoic acid; 15h-20:0, 15-hydroxyeicosanoic acid; 14h-19:0, 14-hydroxynonadecanoic acid.
construct, acyl-CoA oxidase–peroxisome proliferator response element–thymidine kinase–luciferase ((AOx-PPRE)3-TK-luciferase) (Ricote et al. 1998b), contained three copies of the acyl-CoA oxidase PPRE upstream of the Herpes-simplex virus TK promoter. Expression vectors containing the cytomegalovirus IE promoter/enhancer upstream of wild-type mouse PPAR/α (pCMX-mPPAR/α) and human RXR/α (pCMX-hRXR/α) were obtained from Dr R M Evans (The Salk Institute, La Jolla, CA, USA). pcDNA3-mCBP was provided by Dr R Goodman (Oregon Health Science University, Portland, OR, USA) and pcDNA3-hSRC-1 was prepared as described (Torchia et al. 1997). pcDNA3-mTIF2 and pcDNA3-m/CIP were kindly provided by Dr J Torchia, London Regional Cancer Center, London, Ontario, Canada. RAW 264·7 murine macrophages, grown in 24-well plates, were transfected with 0·5 µg each of reporter plasmid and expression plasmid DNA using the calcium phosphate precipitation method. Next morning, CV-1 cells were washed in PBS and fresh media containing PPAR/α ligands dissolved in ethanol (or just ethanol) were added. Luciferase activity of cell homogenates was measured 23–26 h after ligand addition using a Monolight 3010 analytical luminometer (Analytical Luminiscence Laboratory, Sparks, MD, USA).

**Statistical analyses**

Statistical analyses were performed using Student’s t-test.

**Results**

**LDL analyses**

RP-HPLC chromatograms of hydroxy acids in the cholesterol ester, triglyceride and phospholipid fractions of LDL from two of the eight male patients, aged 45–65 years, with intermittent claudication are shown in Fig. 1. Components were collected within a time interval (17–21 min) set by the retention times of authentic 13-HODE and 14-hydroxy-10,13-nonadecadienoate respectively. With the exception of the minor compounds eluted at 15·5 and 15·8 min, no other components displayed UV spectra indicating the presence of conjugated dienes. The were transfected with 0·25 µg each of reporter plasmid and expression plasmid DNA using the calcium phosphate precipitation method. Next morning, CV-1 cells were washed in PBS and fresh media containing PPAR/γ ligands dissolved in ethanol (or just ethanol) were added. Luciferase activity of cell homogenates was measured 23–26 h after ligand addition using a Monolight 3010 analytical luminometer (Analytical Luminiscence Laboratory, Sparks, MD, USA).

**Statistical analyses**

Statistical analyses were performed using Student’s t-test.
components that eluted before and after the designated time interval may have been fatty acids that lacked a conjugated diene or other products of similar polarity. The phospholipid fraction contained the largest amount of LDL monohydroxy acids (Fig. 1A) and smaller amounts were detected in the triglyceride fraction (Fig. 1B). The cholesterol ester fraction did not contain detected amounts of monohydroxy acids (Fig. 1C).

SIM was performed on methyl ester and trimethylsilyl ether derivatives of hydrogenated LDL fatty acids (Fig. 2). Ions characteristic for 9-HODE and 13-HODE as well as 5-, 12- and 15-HETEs were monitored simultaneously (see Table 1). The following semiquantitative mean values were obtained from two separate analyses of LDL pooled from three patients in each case; 9-HODE, 9.3 µg/g LDL protein; 13-HODE, 10.5 µg/g LDL protein; 5-HETE, 0.34 µg/g LDL protein; 12-HETE, 0.14 µg/g LDL protein; and 15-HETE 0.38 µg/g LDL protein.

HODEs and HETEs activate PPARγ in vivo

Activation of PPARγ was studied in transient transfection experiments using GAL4-DBD/PPARγ LBD fusion protein and a reporter plasmid containing four copies of GAL4-DNA binding site linked to an adenovirus E1b minimal promoter and a luciferase reporter gene. RAW 264.7 murine macrophages were transfected and incubated with monohydroxy acids (5 µmol/l) for 24 h. The greatest luciferase activity (Fig. 3) was observed for 9-HODE.

Figure 3 Activation of PPARγ by eicosanoids and HODEs. RAW 264.7 murine macrophages were transfected with 0.5 µg (GAL4)UAS E1b Luc reporter plasmid and 0.5 µg of an expression vector encoding GAL4-DBD/mPPARγ LBD as shown. The transfected cells were treated with 5 µmol/l of the indicated compounds dissolved in ethanol. Control cells were treated with just ethanol. After 23–26 h the cells were harvested, and luciferase activity was determined. The bars represent means ± S.D. of triplicate analyses (*P<0.05, **P<0.01, n=3). Similar results were obtained in three separate experiments. A control experiment with GAL4-DBD alone gave less than 10% of the luciferase activity of the control cells treated with just ethanol.

Figure 4 HETEs and HODEs appear to selectively recruit CBP whereas 15-deoxy-A[12,14]-PGJ2 apparently recruits SRC-1 to PPARγ/RXRα heterodimers. CV-1 cells were transfected with 0.25 µg (AOx-PPRE)3-TK-luciferase reporter plasmid plus 0.25 µg pCMX-mPPARγ and pCMX-hRXRα plasmids. The cells were also transfected with 0.25 µg pCDNA3-hSRC-1 or 0.25 µg pCDNA3-mCBP (A), and with 0.25 µg pCDNA3-mTIF2 or 0.25 µg pCDNA3-mCIP (B). pCDNA3 without insert was used as control. After transfection, the cells were treated with 10 nmol/l LG1069 and either 15-deoxy-A[12,14]-PGJ2 (15d-PGJ2), 13(S)-HODE, 15(S)-HETE or rosiglitazone each at 5 µmol/l. The cells were harvested after 24 h, and assayed for luciferase activity. The bars represent means ± S.D. of triplicate samples and are representative of three independent experiments (*P<0.05, **P<0.01, n=3).
13(S)-HODE and 15(S)-HETE (approximately 20-fold induction) whereas 5(S)-HETE and 12(S)-HETE gave close to 10-fold induction.

**Differential activation of PPARγ/RXRα heterodimers by CBP and SRC-1**

Transient cotransfection experiments were conducted to determine whether different PPARγ ligands exert disparate effects on coactivator recruitment. CV-1 cells were transfected with combinations of plasmids encoding PPARγ, RXRα, CBP, transcriptional mediator/intermediary factor-2 (TIF2), p300/CBP/co-integrator-associated protein (p/CIP) and SRC-1 as indicated in Fig. 4. The transfected cells were then treated with the RXR-specific ligand LG1069 (10 nmol/l) combined with one of the following compounds: 13(S)-HODE, 15(S)-HETE, 15-deoxy-A^{12,14}-PGJ_{2} or rosiglitazone (5 µmol/l of each). Cells cotransfected with SRC-1 showed a substantially greater induction of luciferase activity by 15-deoxy-A^{12,14}-PGJ_{2} than control cells without coactivators (Fig. 4A). On the other hand, cotransfection with SRC-1 had very little effect on reporter gene activation induced by 13(S)-HODE, 15(S)-HETE or rosiglitazone whereas cotransfection with CBP led to a marked increase in reporter gene activity induced by 13(S)-HODE, 15(S)-HETE and rosiglitazone (Fig. 4A). Cells cotransfected with TIF2 or p/CIP showed a significant increase in activation of luciferase activity by all ligands as compared with control cells without coactivators (Fig. 4B), and there was no apparent preference for any of the coactivators used (Fig. 4B).

**CBP(1–450) interacts with PPARγ in vitro**

In order to assess the characteristics of the hydroxy acid-induced PPARγ/CBP interactions that occur during transcriptional activation, an *in vitro* interaction (GST-pulldown) assay was used. In this assay, the binding of [^{35}S]methionine-labeled SRC-1 or [^{35}S]methionine-labeled CBP(1–450) to GST-PPARγ fusion protein immobilized on GSH-Sepharose beads was analyzed in the presence of potential ligands. CBP(1–450) bound to PPARγ irrespectively of whether 15-deoxy-A^{12,14}-PGJ_{2} or 15(S) HETE was added or not (Fig. 5). SRC-1 binding, a positive control for ligand-induced coactivator binding, only occurred in the presence of ligands.
Discussion

Lipoxygenase-catalyzed oxidation of LDL appears to be important in the pathogenesis of atherosclerosis (Rankin et al. 1991, Folcik & Cathcart 1994). Furthermore, PPARγ and 15-lipoxygenase have both been found to localize in atherosclerotic plaques (Yla-Herttuala et al. 1990, Ricote et al. 1998a). In the light of that, we conducted experiments to determine the amounts of potential lipoxygenase–formed hydroxy acids in LDL from patients with intermittent claudication. Semiquantitative analyses of HODEs (9–11 µg/g LDL protein) and HETEs (0·1–0·4 µg/g LDL protein) were performed. Similar levels of HODEs as observed before (Jira et al. 1998) were found in LDL from the 45–65 years old atherosclerotic male patients. These levels are probably sufficient for substantial activation of PPARγ within the isolated environment of atherosclerotic plaques, considering that HODE and HETE concentrations of 1·4 and 1·6 µg/ml in our transfection assays. The 15-lipoxygenase products 13(S)-HODE and 15(S)-HETE were the most efficacious hydroxy acids in those assays (Fig. 3).

Some differences in the PPARγ activation induced by hydroxy acids in macrophages as compared with CV-1 cells are apparent: the 15-lipoxygenase products 13(S)-HODE and 15(S)-HETE were most potent in macrophages (Fig. 3), whereas 9-HODE was most potent in CV-1 cells (Nagy et al. 1998). These differences might reflect cell-specific differences in the expression of PPARγ-modulating proteins, such as coactivators or corepressors.

The coactivator protein CBP is involved in PPARγ activation (Smith et al. 1996, Jenster et al. 1997, Mizukami & Taniguchi 1997, Westin et al. 1998) and interacts with nuclear receptors via short LXXLL domains (LXDs) (McInerney et al. 1996, Heery et al. 1997). To study the binding of CBP to liganded PPARγ, the recruitment of a truncated form of CBP, spanning amino acids 1–450, was determined in a GST-pulldown assay (Fig. 5). This CBP mutant contains LXD1, which is contained within the nuclear receptor-interacting domain (Kamei et al. 1996) but lacks LXD2 in the SRC-1 interaction domain (McInerney et al. 1996). Interaction between SRC-1 and PPARγ served as a positive control. CBP (1–450) bound PPARγ in a ligand–independent manner whereas SRC-1 was recruited by PPARγ when liganded to either 15-deoxy-Δ12,14-PGJ2 or 15(S)-HETE (Fig. 5).

Our transfection data indicate that the coactivators SRC-1 and CBP were differentially affected by different PPARγ ligands. However, p/CIP and TIF2 were both recruited to liganded receptor equally well in the presence of the different ligands (Fig. 4B). An obvious difference between the GST–pulldown results (Fig. 5) and the transfection data (Fig. 4) was observed for 15(S)-HETE, which in GST–pulldown induced SRC-1 binding to PPARγ even though no significant potentiation by SRC-1 was observed in transfection experiments. This discrepancy could be due to the fact that the GST-pulldown assay uses PPARγ which is not heterodimerized to RXRα and not bound to DNA, whereas in transfection assays PPARγ/RXRα heterodimers are DNA-bound.

An implication of our results is that different PPARγ ligands exert disparate effects on the recruitment of coactivator proteins. This in turn may be due to differences in the ligand-induced conformational change of PPARγ/RXRα heterodimers bound to DNA. 13(S)-HODE and 15(S)-HETE caused a change that promotes interaction with CBP but not with SRC-1, whereas 15-deoxy-Δ12,14-PGJ2 apparently induces changes that attract SRC-1. It is not unlikely that such ligand-specific conformational control may also occur in other nuclear or plasma membrane–bound receptors.

In this investigation we have demonstrated the presence of several HODEs and HETEs in LDL from patients with clinical manifestations of atherosclerosis and shown that these compounds exert distinct and specific effects on gene expression mediated by the nuclear receptor PPARγ. Although these effects might have relevance for the pathogenesis of atherosclerosis, no causal relationship should be concluded from the present results. The observations are, however, of interest as they suggest possible mechanisms for the atherogenic properties of oxidized LDL.

Acknowledgements

We thank Marie Waldén for skilful technical assistance, Kristina Loinder for making the CBP(1–450) construct, Cecilia Trinks for help with GST–pulldown experiments, and Gunnar Almroth, Britt Sigfridsson and Ylva Svensson for preparing LDL. This work was supported by grants from the Swedish Medical Research Council (03X–5914, 12X–12544, and 19X–6962), the Swedish Cancer Society (3930–B00–04 XBB) and from the County Council of Östergötland.

References


Differential recruitment of coactivator proteins


McInermey EM, Tsi Mj, O’Malley BW & Katzenellenbogen BS 1996 Analysis of estrogen receptor transcriptional enhancement by a nuclear hormone receptor coactivator. PNAS 93: 10069–10073.


Mizukami J & Taniguchi T 1997 The antidiabetic agent thiazolidinedione stimulates the interaction between PPARγ and CBP. Biochemical and Biophysical Research Communications 240: 61–64.


Received 10 January 2003
Accepted 23 January 2003